Floatz logo

cd4+cd25+ regulatory t cells

Allogeneic Hematopoietic Cell Transplantation (HCT)

Stanford UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Allogeneic Hematopoietic Cell Transplantation (HCT) cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3B
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3B
Tucidinostat
Institute of Hematology & Blood Diseases Hospital, China
Phase 2CCC
TACROLIMUS
Stanford University
Phase 1CC
Evomela
Stanford University
Phase 1CC

View all 15 →

Same molecule, other indications

cd4+cd25+ regulatory t cells is also rated in:

Advanced Hematologic MalignanciesDormant
CC
Indicative ·
43 / 100
View asset →
Myeloproliferative DisordersDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →